Atherothrombosis Research
Atherothrombosis Research - Related Videos
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
0 Views •
Cited by 8 •
2014
The protocol reported here allows the evaluation of the efficacy of photodynamic therapy (PDT) in cell lines and the optimization of the PDT settings before applying the therapy in animal models.
07:32
Human Ex vivo Wound Model and Whole-Mount Staining Approach to Accurately Evaluate Skin Repair
0 Views •
Cited by 17 •
2021
Here we demonstrate an optimized technique for assessing wound repair using ex vivo human skin combined with a whole-mount staining approach. This methodology provides a pre-clinical platform for the evaluation of potential wound therapies.
08:29
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
0 Views •
Cited by 6 •
2019
Here we describe a protocol for the generation of cationic nanoliposomes, which is based on the dry-film method and can be used for the safe and efficient delivery of in vitro transcribed messenger RNA.
10:01
Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
0 Views •
2026
Here, we present a protocol for the structure-guided design of protein-ligand binding interaction between Sanglifehrin A and Cyclophilin A/Ganoderiol-F, essential in discovering new drugs. The stability of the ligand-receptor complex was evaluated using molecular dynamics simulation.
03:38
Aptamer-Based Target Detection Facilitated by a 3-Stage G-Quadruplex Isothermal Exponential Amplification Reaction
0 Views •
Cited by 1 •
2022
The present protocol demonstrates the use of a fast, 3-stage, aptamer-based exponential amplification assay to detect targets. Sample preparation, signal amplification, and color development are covered to implement this system to recognize the presence of theophylline over that of caffeine.
FAQs
Genetic variation can affect several linked features of disease, including lipid metabolism, vascular inflammation, plaque stability, and platelet reactivity. Changes in these features may alter whether a plaque remains stable or becomes more likely to trigger clot formation. Studying these connections helps researchers identify biological pathways that contribute to cardiovascular events rather than treating every patient’s risk as identical.
Inherited genetic variation can shape cardiovascular susceptibility before disease develops, whereas acquired genetic changes may reflect alterations that arise during an individual’s lifetime. Considering both forms broadens the search for mechanisms affecting plaque behavior, platelet activity, and treatment response. This distinction can help researchers separate baseline predisposition from biological changes associated with disease progression or therapy.
Atherothrombosis Research examines lipid metabolism and vascular inflammation as interacting contributors to plaque stability. Genetic differences in these pathways may influence whether plaque remains less disruptive or becomes more vulnerable to rupture or erosion. Clarifying this relationship is important because plaque characteristics help determine the likelihood that thrombogenic material will activate platelets and promote vessel-obstructing clot formation.
Platelet reactivity describes how readily platelets respond to activating signals, and genetic variation may contribute to differences in that response. These differences are relevant when researchers examine why treatment effects can vary among individuals. Linking genetic factors with platelet behavior may improve understanding of antithrombotic response and support strategies that balance prevention of arterial events with patient-specific considerations.
Genetic studies examine inherited and acquired variation alongside pathways involving lipid metabolism, vascular inflammation, plaque stability, platelet reactivity, and treatment response. The goal is to connect variation in these biological features with disease risk and cardiovascular outcomes. This approach can reveal candidate disease-risk pathways and provide a framework for studying why arterial events differ between individuals.
When genetic variation is linked consistently with disease-risk pathways or treatment response, it may help identify biomarkers associated with future cardiovascular events. Such markers can add biological information to risk assessment and improve prediction beyond broad population-level assumptions. In atherothrombosis studies, this work focuses on translating genetic signals into measures that clarify susceptibility and event likelihood.
Genetic information may help distinguish differences in susceptibility, plaque-related biology, platelet reactivity, or response to antithrombotic therapy. Researchers use these relationships to explore more individualized approaches to prevention and treatment rather than relying solely on uniform strategies. The intended outcome is better alignment between a person’s biological risk profile and decisions aimed at reducing cardiovascular events.
Genetics provides a way to study why people differ in lipid handling, vascular inflammation, plaque stability, platelet reactivity, and therapeutic response. These differences can influence the biological conditions associated with arterial events such as heart attack and ischemic stroke. Genetic investigation therefore adds mechanistic context to atherothrombosis research and may support improved prediction, biomarkers, and prevention strategies.